m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00402)
Target Name Superoxide dismutase [Mn], mitochondrial (SOD2)
Gene Name SOD2
Chromosomal Location 6q25.3
Family iron/manganese superoxide dismutase family
Function
Destroys superoxide anion radicals which are normally produced within the cells and which are toxic to biological systems.
    Click to Show/Hide
Gene ID 6648
Uniprot ID
SODM_HUMAN
HGNC ID
HGNC:11180
Ensembl Gene ID
ENSG00000112096
KEGG ID
hsa:6648
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
SOD2 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Fat mass and obesity-associated protein (FTO) [ERASER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by FTO
Cell Line NB4 cell line Homo sapiens
Treatment: shFTO NB4 cells
Control: shNS NB4 cells
 GSE103494
Regulation
logFC: 8.09E-01
p-value: 6.85E-03
More Results Click to View More RNA-seq Results
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary FTO promotes Bortezomib resistance via m6A-dependent destabilization of Superoxide dismutase [Mn], mitochondrial (SOD2) expression in multiple myeloma.
Target Regulation Down regulation
Responsed Disease Multiple myeloma ICD-11: 2A83.1
 Disease Info 
Responsed Drug Bortezomib Approved
 Drug Info 
Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) [READER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by HNRNPC
Cell Line MG63 cell line Homo sapiens
Treatment: HNRNPC knockdown MG63 cells
Control: Wild type MG63 cells
 GSE63086
Regulation
logFC: -1.14E+00
p-value: 6.60E-05
More Results Click to View More RNA-seq Results
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [2]
Response Summary SNP rs5746136 affects m6A modification and regulate Superoxide dismutase [Mn], mitochondrial (SOD2) expression by guiding the binding of hnRNPC to SOD2, which played a critical tumor suppressor role in bladder cancer cells by promoting cell apoptosis and inhibiting proliferation, migration and invasion.
Target Regulation Up regulation
Responsed Disease Bladder cancer ICD-11: 2C94
 Disease Info 
Cell Process Cell apoptosis
Cell proliferation
Cell migration
Cell invasion
In-vitro Model EJ (Human bladder cancer cells)
J82 Bladder carcinoma Homo sapiens CVCL_0359
Multiple myeloma [ICD-11: 2A83]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary FTO promotes Bortezomib resistance via m6A-dependent destabilization of Superoxide dismutase [Mn], mitochondrial (SOD2) expression in multiple myeloma.
Responsed Disease Multiple myeloma [ICD-11: 2A83.1]
Target Regulator Fat mass and obesity-associated protein (FTO) ERASER
 Regulator Info 
Target Regulation Down regulation
Responsed Drug Bortezomib Approved
 Drug Info 
Bladder cancer [ICD-11: 2C94]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [2]
Response Summary SNP rs5746136 affects m6A modification and regulate Superoxide dismutase [Mn], mitochondrial (SOD2) expression by guiding the binding of hnRNPC to SOD2, which played a critical tumor suppressor role in bladder cancer cells by promoting cell apoptosis and inhibiting proliferation, migration and invasion.
Responsed Disease Bladder cancer [ICD-11: 2C94]
Target Regulator Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) READER
 Regulator Info 
Target Regulation Up regulation
Cell Process Cell apoptosis
Cell proliferation
Cell migration
Cell invasion
In-vitro Model EJ (Human bladder cancer cells)
J82 Bladder carcinoma Homo sapiens CVCL_0359
Bortezomib [Approved]
 Drug Info 
In total 1 item(s) under this drug
Experiment 1 Reporting the m6A-centered Drug Response [1]
Response Summary FTO promotes Bortezomib resistance via m6A-dependent destabilization of Superoxide dismutase [Mn], mitochondrial (SOD2) expression in multiple myeloma.
Target Regulator Fat mass and obesity-associated protein (FTO) ERASER
 Regulator Info 
Target Regulation Down regulation
Responsed Disease Multiple myeloma ICD-11: 2A83.1
 Disease Info 
References
Ref 1 FTO promotes Bortezomib resistance via m6A-dependent destabilization of SOD2 expression in multiple myeloma. Cancer Gene Ther. 2022 Feb 10. doi: 10.1038/s41417-022-00429-6. Online ahead of print.
Ref 2 Genetic variants in N6-methyladenosine are associated with bladder cancer risk in the Chinese population. Arch Toxicol. 2021 Jan;95(1):299-309. doi: 10.1007/s00204-020-02911-2. Epub 2020 Sep 22.